Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy. - Seung Tae Kim; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Won Ki Kang; Ho Yeong Lim; Kim, Seung Tae; Lee, Jeeyun; Park, Se Hoon; Park, Joon Oh; Park, Young Suk; et al. (BMC Cancer, 2017)